NanoViricides, Inc. Has Filed its Annual Report
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections...
Pharmaceutical
Avel eCare Recognized as a Top Telemedicine Service by Healthcare Business Review
SIOUX FALLS, SD / ACCESS Newswire / September 30, 2025 / Avel eCare has been named among the Top Telemedicine...
Avel eCare Recognized as a Top Telemedicine Service by Healthcare Business Review
SIOUX FALLS, SD / ACCESS Newswire / September 30, 2025 / Avel eCare has been named among the Top Telemedicine...
Bausch Health’s Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer...
Bausch Health’s Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer...
Expert Facial Plastic Surgeon Explains How Lower Blepharoplasty with Fat Transfer Addresses Puffiness and Volume Loss
Dr. Nicole Schrader outlines the benefits of lower blepharoplasty with fat transfer, a procedure that blends tissue removal with natural...
Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies
TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. ("Wellgistics Health" or the "Company") (NASDAQ:WGRX), a...
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI,...
CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerhouse Dispensary Smoking Scholars
With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised...
Bausch Health to Announce Third Quarter 2025 Results on October 29
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025...
AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection
Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditionsGenerating actionable insights into how cardiac responses...
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market
Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwideVANCOUVER, British Columbia, Sept. 30, 2025...
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of...
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and...
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage...
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseasesZURICH, SWITZERLAND,...
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with...